• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M

    8/1/24 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email

    YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024.

    InMode Logo (PRNewsfoto/InMode)

    Second Quarter 2024 Highlights:

    • Quarterly GAAP revenue of $86.4 million, a decrease of 36.5% compared to the second quarter of 2023. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 87% of its quarterly revenues, while 6% were derived from InMode's traditional laser and non-invasive RF platforms and 7% were derived from InMode's hands-free platforms. Pro-forma revenue (including pre-orders of new platforms not yet delivered) of $102.6 million.
    • GAAP net income of $23.8 million, compared to $55.7 million in the second quarter of 2023; *non-GAAP net income of $29.0 million, compared to $62.2 million in the second quarter of 2023.**Pro-Forma non-GAAP net income of $39.8 million.
    • GAAP diluted earnings per share of $0.28, compared to $0.65 in the second quarter of 2023; *non-GAAP diluted earnings per share of $0.34, compared to $0.72 in the second quarter of 2023.**Pro-Forma non-GAAP diluted earnings per share of $0.46.
    • Quarterly revenues from consumables and service of $21.0 million, a decrease of 3% compared to the second quarter of 2023.
    • Total cash position of $729.2 million as of June 30, 2024, including cash and cash equivalents, marketable securities, and short-term bank deposits.

     

    U.S. GAAP Results

    (U.S. dollars in thousands, except for per share data)



     Q2 2024

    Q2 2023

    Revenues

    $86,449

    $136,081

    Gross Margins

    80 %

    84 %

    Net Income

    $23,818

    $55,729

    Earnings per Diluted Share

    $0.28

    $0.65

    *Non-GAAP Results

    (U.S. dollars in thousands, except for per share data)



    Q2 2024

    Q2 2023

    Gross Margins

    81 %

    84 %

    Net Income

    $28,976

    $62,234

    Earnings per Diluted Share

    $0.34

    $0.72

    **Pro-Forma Non-GAAP Results

    (U.S. dollars in thousands, except for per share data)



     Q2 2024

    Q2 2023

    Revenue

    $102,622

    $136,081

    Gross Margins

    82 %

    84 %

    Net Income

    $39,764

    $62,234

    Earnings per Diluted Share

    $0.46

    $0.72



    *Please refer to "Use of non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A

    reconciliation between U.S. GAAP and non-GAAP Statement of Income
    is provided following the financial statements that are included in

    this release. Non-GAAP results exclude share-based compensation adjustments.

    ** Pro-forma non-GAAP results includes pre-orders of new platforms not yet delivered and excludes share-based compensation.

     

     

    Management Comments

    "The second quarter was challenging for InMode and for the aesthetics industry in general," said Moshe Mizrahy, Chief Executive Officer. "The quarter was impacted mainly by macroeconomic factors and longer production time of new and complex platforms. However, we are encouraged by the level of interest and orders of our new platforms, Ignite and Optimus Max, and we believe that these advanced platforms will be growth catalysts.

    "In addition, as the leading company in the industry, we continue to invest in research and development, and our innovation pipeline is strong. As we offer unique platforms and technologies that require adjustments to the production lines, I would like to recognize the commitment and dedication of our employees who work tirelessly to expedite the production and fulfill orders during these times," Mizrahy concluded.

    Second Quarter 2024 Financial Results

    Total GAAP revenues for the second quarter of 2024 reached $86.4 million, a decrease of 36.5% compared to $136.1 million in second quarter of 2023. Pro-forma revenue reached $102.6 million.

    "During the second quarter, we began delivering the new platforms and we are on track to complete all deliveries within the next several months," said Yair Malca, Chief Financial Officer. "Additionally, we are pleased to report that by the end of July 2024 we have successfully completed our third share repurchase program, acquiring 8.37 million shares for the amount of $150 million."

    GAAP gross margin for the second quarter of 2024 was 80% compared to a gross margin of 84% for the Second quarter of 2023. *Non-GAAP gross margin for the second quarter of 2024 was 81% compared to a gross margin of 84% for the second quarter of 2023.

    **Pro-forma non-GAAP gross margin for the second quarter of 2024 was 82%.

    GAAP operating margin for the second quarter of 2024 was 21%, compared to an operating margin of 42% in the Second quarter of 2023. *Non-GAAP operating margin for the second quarter of 2024 was 27% compared to 47% for the Second quarter of 2023. **Pro-forma non-GAAP operating margin for the second quarter of 2024 was 34%. This decrease was primarily attributable to the decrease in systems sales in North America.

    InMode reported GAAP net income of $23.8 million, or $0.28 per diluted share, in the second quarter of 2024, compared to $55.7 million, or $0.65 per diluted share, in the second quarter of 2023. On a *non-GAAP basis, InMode reported net income of $29.0 million, or $0.34 per diluted share, in the second quarter of 2024, compared to $62.2 million, or $0.72 per diluted share, in the second quarter of 2023. **Pro-forma non-GAAP net income of $39.8 million, or $0.46 per diluted share, in the second quarter of 2024.

    2024 Financial Outlook

    Management provided an outlook for the full year of 2024 ending December 31, 2024. Based on our current estimates, management expects:

    • Full Year 2024 revenue to be $430 to $440 million compared to prior guidance of $485 million to $495 million
    • *Non-GAAP gross margin between 82% and 84% consistent with prior guidance
    • *Non-GAAP income from operations between $150 million and $155 million compared to prior guidance of $169 million to $174 million
    • *Non-GAAP earnings per diluted share between $1.92 and $1.96 compared to previous guidance of $2.01 to $2.05


    This outlook is not a guarantee of future performance, and stockholders should not rely on such forward-looking statements. See "Forward-

    Looking Statements" for additional information.



    *Please refer to "Use of non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A

    reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in

    this release. Non-GAAP results exclude share-based compensation adjustments.



    ** Pro-forma non-GAAP results includes pre-orders of new platforms not yet delivered and excludes share-based compensation.



    Based on our 2024 Financial Outlook, it is not expected that there should be any difference between our Pro-forma non-GAAP results and

    our non-GAAP results for the full year 2024.

    The Current Situation in Israel

    Regarding the current situation in Israel, management would like to assure investors that the Company is prioritizing the safety and well-being of its employees, and all its team are safe. However, an inability to promptly receive needed supplies and materials due to the ongoing and unpredictable nature of the conflict in Israel and the surrounding region may adversely impact our ability to commercialize and manufacture our product candidates and products in a timely manner. This could cause several delays and/or issues for our operations, which in turn would have a material adverse impact on our ability to commercialize our product candidates and our financial condition.

    Use of Non-GAAP Financial Measures

    In addition to InMode's operating results presented in accordance with GAAP, this release contains certain non-GAAP financial measures including non-GAAP net income, non-GAAP earnings per diluted share, non-GAAP operating margin as well as Pro-forma Non-GAAP revenue, pro-forma Non-GAAP net income, pro-forma non-GAAP earnings per diluted share and pro-forma non-GAAP operating margin. Because these measures are used in InMode's internal analysis of financial and operating performance, management believes they provide investors with greater transparency of its view of InMode's economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode's GAAP operating results, allows investors to more effectively evaluate and compare InMode's performance to that of its peers, although InMode's presentation of its non-GAAP measures may not be strictly comparable to the similarly titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release.

    Conference Call Information

    Mr. Moshe Mizrahy, Chief Executive Officer, Dr. Michael Kreindel, Co-Founder and Chief Technology Officer, Mr. Yair Malca, Chief Financial Officer, Mr. Shakil Lakhani, President of North America, will host a conference call today, August 1, 2024, at 8:30 a.m. Eastern Time to discuss the second 2024 financial results.

    The Company encourages participants to pre-register for the conference call using the following link: 

    https://dpregister.com/sreg/10190152/fcd9be3160.

    Callers will receive a unique dial-in number upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.

    For callers who opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.

    U.S. Toll-Free Dial-in Number: 1-833-316-0562

    Israel Toll- Free Dial-in Number: 1-80-921-2373

    International Dial-in Number: 1-412-317-5736

    Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=GpRhmBhV

    At:

    8:30 a.m. Eastern Time

    5:30 a.m. Pacific Time

    The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from August 1, 2024, at 12 p.m. Eastern Time to August 15, 2024, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers: 

    Replay Dial-in U.S TOLL-FREE: 1-877-344-7529

    Replay Dial-in Canada TOLL-FREE: 855-669-9658

    Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088

    Replay Pin Number: 2791553

    To access the replay using an international dial-in number, please select the link below: 

    https://services.choruscall.com/ccforms/replay.html

    A replay of the conference call will also be available for 90 days on InMode's website at https://inmodemd.com/investors/.

    About InMode

    InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

    Forward-Looking Statements 

    The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the 2024 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 13, 2024, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

    Company Contact:

    Yair Malca

    Chief Financial Officer

    Phone: (949) 305-0108

    Email: [email protected]

    Investor Relations Contact:

    Miri Segal

    MS-IR LLC

    Email: [email protected]

     

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    Three months ended

    June 30,

    Six months ended

    June 30,



    2024

    2023

    2024

    2023



    REVENUES

    86,449

    136,081

    166,733

    242,155



    COST OF REVENUES

    17,116

    22,054

    33,481

    40,308



    GROSS PROFIT

    69,333

    114,027

    133,252

    201,847



    OPERATING EXPENSES:











    Research and development

    3,698

    3,567

    7,216

    6,669



    Sales and marketing

    45,055

    51,059

    84,850

    92,772



    General and administrative

    2,266

    2,392

    4,780

    4,400



    TOTAL OPERATING EXPENSES

    51,019

    57,018

    96,846

    103,841



    OPERATIONS INCOME

    18,314

    57,009

    36,406

    98,006



    Finance income, net

    8,690

    4,445

    16,674

    7,734



    INCOME BEFORE INCOME TAXES

    27,004

    61,454

    53,080

    105,740



    INCOME TAXES

    3,186

    5,725

    5,566

    9,506



    NET INCOME

    23,818

    55,729

    47,514

    96,234















    EARNINGS PER SHARE:











    Basic

    0.28

    0.67

    0.56

    1.16



    Diluted

    0.28

    0.65

    0.55

    1.12



    WEIGHTED AVERAGE NUMBER OF SHARES

    OUTSTANDING USED IN COMPUTATION OF

    EARNINGS PER SHARE (in thousands)











    Basic

    83,878

    83,405

    84,205

    83,280



    Diluted

    85,890

    85,650

    86,520

    85,579



     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    June 30,

    2024

    December 31,

    2023

    Assets





    CURRENT ASSETS:





    Cash and cash equivalents

    91,997

    144,411

    Marketable securities

    333,517

    373,647

    Short-term bank deposits

    303,694

    223,547

    Accounts receivable, net of allowance for credit losses

    38,154

    42,362

    Prepaid expense and other receivables

    23,003

    16,268

    Inventories

    52,627

    45,095

             TOTAL CURRENT ASSETS

    842,992

    845,330

        NON-CURRENT ASSETS:





    Accounts receivable, net of allowance for credit losses

    3,100

    3,670

    Deferred income tax asset

    1,402

    1,506

    Operating lease right-of-use assets

    9,246

    9,698

    Property and equipment, net

    2,396

    2,382

    Other investments

    700

    700

    TOTAL NON-CURRENT ASSETS

    16,844

    17,956

    TOTAL ASSETS

    859,836

    863,286

    Liabilities and shareholders' equity





    CURRENT LIABILITIES:





    Accounts payable

    15,548

    13,966

    Contract liabilities

    43,610

    10,923

    Other liabilities

    38,532

    39,247

    TOTAL CURRENT LIABILITIES

    97,690

    64,136

        NON-CURRENT LIABILITIES:





    Contract liabilities

    3,455

    3,766

    Other liabilities

    1,899

    1,399

    Operating lease liabilities

    5,671

    6,613

    TOTAL NON-CURRENT LIABILITIES

    11,025

    11,778

    TOTAL LIABILITIES

    108,715

    75,914







    TOTAL SHAREHOLDERS' EQUITY

    751,121

    787,372

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

    859,836

    863,286

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)







    Three months ended

    June 30,

    Six months ended

    June 30,



    2024

    2023

    2024

    2023



    CASH FLOWS FROM OPERATING ACTIVITIES:











    Net income

    23,818

    55,729

    47,514

    96,234



    Adjustments required to reconcile net income to net cash provided by operating activities:











    Depreciation and amortization

    177

    184

    342

    372



    Share-based compensation expenses

    5,158

    6,505

    9,141

    10,714



    Change in allowance for credit losses of trade receivable

    97

    261

    284

    239



    Loss on marketable securities, net

    112

    -

    141

    -



    Finance income, net

    (5,040)

    (1,197)

    (9,797)

    (2,709)



    Deferred income taxes

    (56)

    43

    (93)

    62



    Changes in operating assets and liabilities:











    Decrease (increase) in accounts receivable

    (4,814)

    (7,949)

    4,494

    (5,708)



    Increase in other receivables

    (4,048)

    (3,791)

    (6,717)

    (4,020)



    Decrease (increase) in inventories

    (1,025)

    2,243

    (7,532)

    1,329



    Increase (decrease) in accounts payable

    2,325

    1,308

    1,582

    (2,947)



    Increase (decrease) in other liabilities

    2,241

    7,211

    (5,562)

    (15,832)



    Increase (decrease) in contract liabilities (current and non-current)

    23,114

    (7,547)

    32,376

    (3,621)



    Net cash provided by operating activities

    42,059

    53,000

    66,173

    74,113



    CASH FLOWS FROM INVESTING ACTIVITIES:











       Investment in short-term deposits

    (55,000)

    (25,000)

    (86,297)

    (28,000)



       Proceeds from short-term deposits

    13,500

    31,500

    13,500

    34,500



       Purchase of fixed assets

    (246)

    (194)

    (358)

    (535)



       Purchase of marketable securities

    (64,129)

    (54,190)

    (185,693)

    (132,119)



       Proceeds from sale of marketable securities

    33,910

    -

    47,375

    -



       Proceeds from maturity of marketable securities

    89,690

    60,891

    181,808

    111,605



    Net cash provided by (used in) investing activities

    17,725

    13,007

    (29,665)

    (14,549)



    CASH FLOWS FROM FINANCING ACTIVITIES:











      Repurchase of ordinary shares

    (88,980)

    -

    (88,980)

    -



           Exercise of options

    395

    827

    629

    2,500



    Net cash provided by (used in) financing activities

    (88,585)

    827

    (88,351)

    2,500



    EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH

    EQUIVALENTS

    (132)

    60

    (571)

    251



    NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

    (28,933)

    66,894

    (52,414)

    62,315















    CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

    120,930

    92,961

    144,411

    97,540



    CASH AND CASH EQUIVALENTS AT END OF PERIOD

    91,997

    159,855

    91,997

    159,855



     

    Revision of prior period financial information

    The Company revised certain items within the investing activities with no impact on the net cash used in investing activities. The items impacted were "Investment in short-term deposits" and "Proceeds from short-term deposits" which were decreased by $75,000 and $78,000 for the three months and six months ended June 30,2023 respectively and "Purchase of marketable securities" and "Proceeds from maturity of marketable securities" which were decreased by $0, and $40,423 for the three months and six months ended June 30, 2023.

    These changes have no impact on our previously reported consolidated total cash flows from operating activities, financing activities and investing activities in the periods stated above as well as net income and net change in cash and cash equivalents.

    The Company evaluated the materiality of the adjustments, individually and in the aggregate, considering both qualitative and quantitative factors, and concluded that it was immaterial to the Company's prior periods' consolidated financial information. Since the revision was not material to any prior interim period or annual consolidated financial statements, no amendments to previously filed interim or annual periodic financial information was required. Consequently, the Company has revised the historical consolidated financial information presented herein for the impact of the above.

     

     

    INMODE LTD.

    CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)





    Three months ended June 30,

    Six months ended June 30,

    2024

    2023

    2024

    2023

    Revenues by Category:



































    Capital Equipment revenues - United States

    34,799

    41 %

    73,828

    54 %

    65,658

    39 %

    123,579

    51 %

    Capital Equipment revenues - International

    30,606

    35 %

    40,635

    30 %

    57,529

    35 %

    77,008

    32 %

    Total Capital Equipment revenues

    65,405

    76 %

    114,463

    84 %

    123,187

    74 %

    200,587

    83 %

    Consumables and service revenues

    21,044

    24 %

    21,618

    16 %

    43,546

    26 %

    41,568

    17 %

    Total Revenue

    86,449

    100 %

    136,081

    100 %

    166,733

    100 %

    242,155

    100 %

























     

     



    Three months ended June 30,

    Six months ended June 30,

    2024

    2023

    2024

    2023



    %

    %

    %

    %



    United States

    International

    Total

    United States

    International

    Total

    United States

    International

    Total

    United States

    International

    Total

    Revenues by Technology:

























    Minimal-Invasive

    85

    86

    87

    86

    73

    81

    87

    84

    86

    88

    74

    83

    Hands-Free

    11

    4

    7

    11

    6

    9

    9

    3

    6

    10

    6

    8

    Non-Invasive

    4

    10

    6

    3

    21

    10

    4

    13

    8

    2

    20

    9



    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

    100

     

     

    INMODE LTD.

    RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF

     INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME 

    (U.S. dollars in thousands, except for per share data)

    (Unaudited)









     

    Three months ended June 30, 2024

     

    Three months ended June 30, 2023



     

     

     

    GAAP

     

     

    Share Based

    Compensation

     

     

     

    Non-GAAP

     

     

     

    GAAP

     

     

    Share Based

    Compensation

     

     

     

    Non-GAAP



    REVENUES

    86,449

    -

    86,449

    136,081

    -

    136,081



    COST OF REVENUES

    17,116

    (471)

    16,645

    22,054

    (547)

    21,507



    GROSS PROFIT

    69,333

    471

    69,804

    114,027

    547

    114,574



    OPERATING EXPENSES:















    Research and development

    3,698

    (559)

    3,139

    3,567

    (757)

    2,810



    Sales and marketing

    45,055

    (3,824)

    41,231

    51,059

    (4,731)

    46,328



    General and administrative

    2,266

    (304)

    1,962

    2,392

    (470)

    1,922



    TOTAL OPERATING

    EXPENSES

     

    51,019

     

    (4,687)

     

    46,332

     

    57,018

     

    (5,958)

    51,060



    OPERATIONS INCOME

    18,314

    5,158

    23,472

    57,009

    6,505

    63,514



    Finance income (expense), net

     

    8,690

     

    -

     

    8,690

     

    4,445

     

    -

    4,445



    INCOME BEFORE INCOME TAXES

    27,004

    5,158

    32,162

    61,454

    6,505

    67,959



    INCOME TAXES

    3,186

    -

    3,186

    5,725

    -

    5,725



    NET INCOME

    23,818

    5,158

    28,976

    55,729

    6,505

    62,234



















    EARNINGS PER SHARE:















    Basic

     

    0.28



     

    0.35

     

    0.67



    0.75



    Diluted

    0.28



    0.34

    0.65



    0.72



    WEIGHTED AVERAGE NUMBER OF

    SHARES OUTSTANDING USED IN

    COMPUTATION OF EARNINGS PER

    SHARE (in thousands)















    Basic

    83,878



    83,878

    83,405



    83,405



    Diluted

    85,890



    85,900

    85,650



    86,243



     

     



    Six months ended June 30, 2024

    Six months ended June 30, 2023

    GAAP

    Share Based

    Compensation

    Non-GAAP

    GAAP

    Share Based

    Compensation

    Non-GAAP

    REVENUES

    166,733

    -

    166,733

    242,155

    -

    242,155

    COST OF REVENUES

    33,481

    (880)

    32,601

    40,308

    (901)

    39,407

    GROSS PROFIT

    133,252

    880

    134,132

    201,847

    901

    202,748

    OPERATING EXPENSES:













    Research and development

    7,216

    (987)

    6,229

    6,669

    (1,258)

    5,411

    Sales and marketing

    84,850

    (6,707)

    78,143

    92,772

    (7,769)

    85,003

    General and administrative

    4,780

    (567)

    4,213

    4,400

    (786)

    3,614

    TOTAL OPERATING EXPENSES

    96,846

    (8,261)

    88,585

    103,841

    (9,813)

     

    94,028

    OPERATIONS INCOME

    36,406

    9,141

    45,547

    98,006

    10,714

     

    108,720

    Finance income (expense),net

    16,674

    -

    16,674

    7,734

    -

    7,734

    INCOME BEFORE INCOME TAXES

    53,080

    9,141

    62,221

    105,740

    10,714

    116,454

    INCOME TAXES

    5,566

    -

    5,566

    9,506

    -

    9,506

    NET INCOME

    47,514

    9,141

    56,655

    96,234

    10,714

    106,948















    EARNINGS PER SHARE:













    Basic

    0.56



    0.67

    1.16



    1.28

    Diluted

    0.55



    0.65

    1.12



    1.24

    WEIGHTED AVERAGE NUMBER OF

    SHARES OUTSTANDING USED IN

    COMPUTATION OF EARNINGS PER

    SHARE (in thousands)













    Basic

    84,205



    84,205

    83,280



    83,280

    Diluted

    86,520



    86,531

    85,579



    86,062

     

    Logo: https://mma.prnewswire.com/media/1064477/4839231/InMode_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inmode-reports-second-quarter-2024-financial-results-quarterly-revenue-of-86-4m-represents-36-5-year-over-year-decrease-pro-forma-revenue-including-new-platform-pre-orders-not-yet-delivered-of-102-6m-302211666.html

    SOURCE InMode LTD

    Get the next $INMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    SEC Filings

    View All

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    3/13/26 7:00:09 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    2/23/26 7:00:19 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-8 filed by InMode Ltd.

    S-8 - InMode Ltd. (0001742692) (Filer)

    2/10/26 7:38:08 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by InMode Ltd.

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:09:10 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by InMode Ltd.

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:06:52 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Mizrahy Moshe

    3 - InMode Ltd. (0001742692) (Issuer)

    3/18/26 7:08:06 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

    Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern TimeYOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2026 before the Nasdaq market opens on Wednesday, May 6, 2026. InMode is currently finalizing its financial results for the first quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I

    4/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Present at the 25th Annual Needham Virtual Healthcare Conference

    YOKNEAM, Israel, March 24, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026. The fireside chat, moderated by Michael Matson, Senior Equity Analyst, is scheduled for 11:00 am Eastern Time on Monday, April 13, and a live webcast of the presentation can be accessed here. InMode will also hold virtual one-on-one investor meetings

    3/24/26 8:30:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Announces New Share Repurchase Program

    YOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a new share repurchase program for up to approximately 10% of the Company's total shares outstanding, representing approximately 6.38 million ordinary shares. In 2025, the Company repurchased approximately $127.4 million of its outstanding ordinary shares through share repurchase programs. Despite a challenging macroeconomic environment, the Company continues to generate strong cash fl

    3/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InMode downgraded by BTIG Research

    BTIG Research downgraded InMode from Buy to Neutral

    4/29/25 8:06:22 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

    4/28/25 1:56:11 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on InMode with a new price target

    BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

    10/17/24 7:41:34 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Financials

    Live finance-specific insights

    View All

    InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

    Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern TimeYOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2026 before the Nasdaq market opens on Wednesday, May 6, 2026. InMode is currently finalizing its financial results for the first quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I

    4/13/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million

    YOKNEAM, Israel, Feb. 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights: Quarterly GAAP revenues of $103.9 million, compared to $97.9 million in the fourth quarter of 2024.Quarterly revenues from consumables and service of $21.5 million, an increase of 8% compared to the fourth quarter of 2024.GAAP operation income of $26 million, *non-GAAP operation income of $28.5 million.Total cash position of $555.3 million as of December 31, 2025, including cash and cash equivalents, marketable securiti

    2/10/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026, Expects Q4 Revenue Between $103.6M-$103.8M

    Conference call to be held on Tuesday, February 10, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Jan. 8, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year of 2025 before the Nasdaq market opens on Tuesday, February 10, 2026. InMode is currently finalizing its financial results for the fourth quarter and full year of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and ot

    1/8/26 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Leadership Updates

    Live Leadership Updates

    View All

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:31:18 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:25:40 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by InMode Ltd.

    SC 13G - InMode Ltd. (0001742692) (Subject)

    2/6/24 9:36:39 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care